LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 218

Search options

  1. Article ; Online: Corrigendum to "Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder" [Clinical Immunology 241 (2022) 109072].

    Magro, Giuseppe

    Clinical immunology (Orlando, Fla.)

    2022  Volume 244, Page(s) 109129

    Language English
    Publishing date 2022-09-21
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 1459903-x
    ISSN 1521-7035 ; 1521-6616
    ISSN (online) 1521-7035
    ISSN 1521-6616
    DOI 10.1016/j.clim.2022.109129
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 880: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.

    Magro, Giuseppe

    Clinical immunology (Orlando, Fla.)

    2022  Volume 241, Page(s) 109072

    Abstract: Satralizumab, an antibody against IL-6R, has been recently approved in Neuromyelitis optica spectrum disorder(NMOSD). Targeting IL-6 or IL-6 Receptor(like Satralizumab does) results in inhibition of both pro and anti-inflammatory pathways of IL-6. ... ...

    Abstract Satralizumab, an antibody against IL-6R, has been recently approved in Neuromyelitis optica spectrum disorder(NMOSD). Targeting IL-6 or IL-6 Receptor(like Satralizumab does) results in inhibition of both pro and anti-inflammatory pathways of IL-6. Sgp130FC(Olamkicept) is a monoclonal antibody that prevents only the proinflammatory pathway of IL-6 to be activated, and could represent a better way to target IL-6 pathway in Neuromyelitis optica spectrum disorder.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Humans ; Interleukin-6 ; Neuromyelitis Optica/drug therapy ; Neuromyelitis Optica/metabolism ; Signal Transduction
    Chemical Substances Antibodies, Monoclonal ; Interleukin-6
    Language English
    Publishing date 2022-07-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1459903-x
    ISSN 1521-7035 ; 1521-6616
    ISSN (online) 1521-7035
    ISSN 1521-6616
    DOI 10.1016/j.clim.2022.109072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 880: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.

    Magro, Giuseppe

    Multiple sclerosis and related disorders

    2022  Volume 65, Page(s) 104037

    Abstract: Satralizumab, the monoclonal antibody against IL-6R, has been approved not long ago in Neuromyelitis Optica Spectrum Disorder (NMOSD). Nonetheless, inhibiting IL-6 Receptor might not be enough, since Satralizumab results in inhibition of both pro and ... ...

    Abstract Satralizumab, the monoclonal antibody against IL-6R, has been approved not long ago in Neuromyelitis Optica Spectrum Disorder (NMOSD). Nonetheless, inhibiting IL-6 Receptor might not be enough, since Satralizumab results in inhibition of both pro and antiinflammatory pathways of IL-6. The detrimental role of IL-6 in NMOSD could be mainly played by the trans-signaling. Olamkicept (sgp130Fc) is a monoclonal antibody that prevents only the trans-signaling pathway of IL-6 to be activated. Targeting only the trans-signaling pathway (the pro-inflammatory one) with Olamkicept/sgp130Fc could lead to avoidance of potential harmful effect of global IL-6 blockade such as profound immunosuppression and it could also mean leaving the “good side” of IL-6 on, while turning the "bad side" off.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Aquaporin 4 ; Humans ; Neuromyelitis Optica
    Chemical Substances Antibodies, Monoclonal, Humanized ; Aquaporin 4 ; satralizumab (YB18NF020M)
    Language English
    Publishing date 2022-07-07
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2022.104037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Status epilepticus: Is there a Stage 1 plus?

    Magro, Giuseppe / Laterza, Vincenzo

    Epilepsia

    2024  

    Abstract: In status epilepticus (SE), "time is brain." Currently, first-line therapy consists of benzodiazepines (BDZs) and SE is classified by the response to treatment; stage 2 or established SE is defined as "BDZ-resistant SE." Nonetheless, this classification ... ...

    Abstract In status epilepticus (SE), "time is brain." Currently, first-line therapy consists of benzodiazepines (BDZs) and SE is classified by the response to treatment; stage 2 or established SE is defined as "BDZ-resistant SE." Nonetheless, this classification does not always work, especially in the case of prolonged convulsive SE, where many molecular changes occur and γ-aminobutyric acid signaling becomes excitatory. Under these circumstances, BDZ therapy might not be optimal, and might be possibly detrimental, if given alone; as the duration of SE increases, so too does BDZ resistance. Murine models of SE showed how these cases might benefit more from synergistic combined therapy from the start. The definition of Stage 1 plus is suggested, as a stage requiring combined therapy from the start, which includes prolonged SE with seizure activity going on for >10 min, the time that marks the disruption of receptor homeostasis, with increased internalization. This specific stage might require a synergistic approach from the start, with a combination of first- and second-line treatment.
    Language English
    Publishing date 2024-03-20
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 216382-2
    ISSN 1528-1167 ; 0013-9580
    ISSN (online) 1528-1167
    ISSN 0013-9580
    DOI 10.1111/epi.17953
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 517: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 475: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?

    Magro, Giuseppe

    Travel medicine and infectious disease

    2020  Volume 37, Page(s) 101685

    MeSH term(s) Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/drug therapy ; Drug Discovery/methods ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy ; SARS-CoV-2
    Chemical Substances Antiviral Agents
    Keywords covid19
    Language English
    Publishing date 2020-04-22
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2170891-5
    ISSN 1873-0442 ; 1477-8939
    ISSN (online) 1873-0442
    ISSN 1477-8939
    DOI 10.1016/j.tmaid.2020.101685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6236: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.

    Magro, Giuseppe

    Medical hypotheses

    2020  Volume 142, Page(s) 109829

    MeSH term(s) Betacoronavirus ; Blood Coagulation Disorders/blood ; Blood Coagulation Disorders/etiology ; Blood Coagulation Disorders/mortality ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Cytokines/biosynthesis ; Disseminated Intravascular Coagulation/blood ; Disseminated Intravascular Coagulation/etiology ; Disseminated Intravascular Coagulation/mortality ; Fibrin Fibrinogen Degradation Products/metabolism ; Heparin/therapeutic use ; Humans ; Models, Biological ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; SARS-CoV-2
    Chemical Substances Cytokines ; Fibrin Fibrinogen Degradation Products ; fibrin fragment D ; Heparin (9005-49-6)
    Keywords covid19
    Language English
    Publishing date 2020-05-12
    Publishing country United States
    Document type Letter
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.

    Magro, Giuseppe

    Cytokine: X

    2020  Volume 2, Issue 2, Page(s) 100029

    Abstract: Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease ... ...

    Abstract Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.
    Keywords covid19
    Language English
    Publishing date 2020-05-14
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2590-1532
    ISSN (online) 2590-1532
    DOI 10.1016/j.cytox.2020.100029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.

    Magro, Giuseppe

    Virus research

    2020  Volume 286, Page(s) 198070

    Abstract: SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/ ... ...

    Abstract SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir and corticosteroids these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Neutralizing/therapeutic use ; Anticoagulants/therapeutic use ; Antiviral Agents/therapeutic use ; Azetidines/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/virology ; Disseminated Intravascular Coagulation/drug therapy ; Disseminated Intravascular Coagulation/virology ; Drug Combinations ; Heparin/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; Inflammation ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Lopinavir/therapeutic use ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Purines ; Pyrazoles ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Sulfonamides/therapeutic use
    Chemical Substances Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Anticoagulants ; Antiviral Agents ; Azetidines ; Drug Combinations ; Emapalumab ; Interleukin 1 Receptor Antagonist Protein ; Purines ; Pyrazoles ; Sulfonamides ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Hydroxychloroquine (4QWG6N8QKH) ; Heparin (9005-49-6) ; eculizumab (A3ULP0F556) ; tocilizumab (I031V2H011) ; baricitinib (ISP4442I3Y) ; Ritonavir (O3J8G9O825) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-06-20
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605780-9
    ISSN 1872-7492 ; 0168-1702
    ISSN (online) 1872-7492
    ISSN 0168-1702
    DOI 10.1016/j.virusres.2020.198070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1965: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: There is an urgent need to standardize sonothrombolysis!

    Magro, Giuseppe / Tosto, Federico

    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

    2022  , Page(s) 15910199221143181

    Language English
    Publishing date 2022-12-19
    Publishing country United States
    Document type Letter
    ZDB-ID 1354913-3
    ISSN 2385-2011 ; 1591-0199 ; 1123-9344
    ISSN (online) 2385-2011
    ISSN 1591-0199 ; 1123-9344
    DOI 10.1177/15910199221143181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6325: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top